Objective To explore the effects of Tangzhiping granules on the blood glucose and IGF-Ⅰ in T2DM rats.Methods 40 SPF grade Wistar rats whose weight were about (200±20)g were selected as the subjects for this study,one half were male and another half were female.After be adapted to the normal food for 1 week,8 rats were selected randomly from all of rats following their weight as the blank group (ordinary feed).The remaining the others were fed with the high-fat and high-sugar food.The 6th week,the other rats would be undergo intraperitoneal injection once in left lower belly with 40 mg/kg streptozotocin (STZ),and enable them to become T2DM rats.The 8th week,we would select successful animal models 32 which were divided randomly into a modle group,a Tangmaikang (TMK) granules group,a Tangzhiping granules (TZP)group.The 12th week,we would execute all of rats and collect the blood serums which were tested for the blood glucose and IGF-Ⅰ.Results () Compared model group with blank group,the levels of the blood glucose of the model group increased to (28.33±0.50)mmol/L,while the IGF-Ⅰ decreased to (3.40 ± 0.83) pg/ml,which showed the model of type 2 diabetic rats was successfully set up.② The levels of the blood glucose of the Tangzhiping granules group and Tangmaikang granules group were lower than that of the model group to (15.06±0.39)mm ol/L,(20.12±0.58)mmol/L,but the levels of the IGF-Ⅰ were higher to (9.39±2.91)pg/ml,(5.58± 1.09)pg/ml,which implied that each group of pharmacological treatment had a good effect.③ The level of the blood glucose and IGF-Ⅰ of the Tangzhiping granules group was also significantly different from that of the Tangmaikang granule group,the therapeutic effect of Tangzhiping granules group was better than that of Tangmaikang granules group.Conclusion Tangzhiping granules can reduce the blood glucose of T2DM rats.And also can increase IGF-Ⅰ of T2DM rats.Tangzhiping granules can improve the various symptoms of diabetes mellitus at the same time.

Lung cancer is the malignant tumor with the highest morbidity and mortality in China. Non-small cell lung cancer (NSCLC) is the main pathological subtype of lung cancer. On April 13, 2023, the National Comprehensive Cancer Network (NCCN) released the third edition of the 2023 NCCN Oncology Clinical Practice Guidelines: Non-small Cell Lung Cancer, which reflects the latest advances in international lung cancer research. This article will interpret the main updated contents of the new edition of the guidelines, and compare it with the third edition of the NCCN guidelines in 2022, so as to provide references about the diagnosis and treatment of NSCLC for clinical medical personnel in China.
.
Humans ; Carcinoma, Non-Small-Cell Lung ; China ; Lung Neoplasms ; Thorax